2016 Annual Meeting

SC09-Recent Developments in Heart and Lung Transplant Pathology: Navigating the Shifting Sands

Room CC 604, March 18 2016, 8:00am to 11:30am


SC09-Recent Developments in Heart and Lung Transplant Pathology: Navigating the Shifting Sands

Session Credits: 3 CME and 3 SAMs

Faculty: Dylan V. Miller, MD, InterMountainMedical Center and University of Utah, Salt Lake City, UT ; Gerald J. Berry, MD, Stanford University Medical Center, Stanford, CA; Henry D. Tazelaar, MD, Mayo Clinic- Scottsdale, Scottsdale, AZ and John P. Veinot, MD, Ottawa Hospital, Ottawa, ON, Canada

This practically-oriented course will focus on recent updates to the International Society for Heart and Lung Transplantations working formulation for antibody mediated rejection (AMR) in cardiac biopsies as well as recent recommendations regarding AMR in lung transplant biopsies. Through a series of illustrative case presentations, the course will review the most up-to-date scoring criteria for rejection and present general strategies for biopsy handling within the context of rejection surveillance program. A general approach to heart and lung biopsy interpretation and reporting will be discussed and important histopathologic mimics of rejection and significant non-rejection pathology will be presented in the course of the case presentations. Factors to consider in determining the most appropriate use of ancillary testing modalities as well as reporting mechanisms at a given institution will also be addressed. Whole slide images, along with case histories, as well as a course syllabus will be posted on the USCAP website for review by pre-registrants prior to the meeting. All course registrants will also receive web access to the PowerPoint presented at the USCAP Annual Meeting along with the text portion of the syllabus.

Upon completion of this educational activity, participants should be able to:

  1. Recognize biopsy features of cellular rejection in heart and lung allografts (as well as their mimics) and appropriately grade rejection using current ISHLT working formulation.
  2. Recognize biopsy features of antibody mediated rejection of heart and lung allografts (including appropriate use of ancillary techniques) and appropriately grade AMR using current ISHLT criteria.
  3. Articulate a strategy for rejection surveillance (including AMR) in heart and lung transplant biopsies based on published recommendations and guidelines.


view more